1. Home
  2. ALLO vs AIOT Comparison

ALLO vs AIOT Comparison

Compare ALLO & AIOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • AIOT
  • Stock Information
  • Founded
  • ALLO 2017
  • AIOT 1993
  • Country
  • ALLO United States
  • AIOT United States
  • Employees
  • ALLO N/A
  • AIOT N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • AIOT Telecommunications Equipment
  • Sector
  • ALLO Health Care
  • AIOT Telecommunications
  • Exchange
  • ALLO Nasdaq
  • AIOT Nasdaq
  • Market Cap
  • ALLO 677.5M
  • AIOT 687.0M
  • IPO Year
  • ALLO 2018
  • AIOT N/A
  • Fundamental
  • Price
  • ALLO $2.27
  • AIOT $5.95
  • Analyst Decision
  • ALLO Buy
  • AIOT Buy
  • Analyst Count
  • ALLO 12
  • AIOT 1
  • Target Price
  • ALLO $10.06
  • AIOT $10.00
  • AVG Volume (30 Days)
  • ALLO 2.6M
  • AIOT 1.2M
  • Earning Date
  • ALLO 11-07-2024
  • AIOT 11-12-2024
  • Dividend Yield
  • ALLO N/A
  • AIOT N/A
  • EPS Growth
  • ALLO N/A
  • AIOT N/A
  • EPS
  • ALLO N/A
  • AIOT N/A
  • Revenue
  • ALLO $43,000.00
  • AIOT $221,073,000.00
  • Revenue This Year
  • ALLO N/A
  • AIOT $153.13
  • Revenue Next Year
  • ALLO $5,902.96
  • AIOT $21.07
  • P/E Ratio
  • ALLO N/A
  • AIOT N/A
  • Revenue Growth
  • ALLO 26.47
  • AIOT 67.23
  • 52 Week Low
  • ALLO $2.01
  • AIOT $2.22
  • 52 Week High
  • ALLO $5.78
  • AIOT $6.68
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 36.00
  • AIOT 61.29
  • Support Level
  • ALLO $2.95
  • AIOT $4.80
  • Resistance Level
  • ALLO $3.36
  • AIOT $6.68
  • Average True Range (ATR)
  • ALLO 0.26
  • AIOT 0.38
  • MACD
  • ALLO -0.06
  • AIOT 0.09
  • Stochastic Oscillator
  • ALLO 0.91
  • AIOT 62.18

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

About AIOT PowerFleet Inc. Common Stock

PowerFleet Inc is engaged in Internet-of-Things (IoT) solutions providing valuable business intelligence for managing high-value enterprise assets that improve operational efficiencies. It provide critical information that powers unified operations throughout organizations. It is solving the challenge of inefficient data collection, real-time visibility, and analysis that leads to transformative business operations. Its SaaS cloud-based applications take data from IoT devices and ecosystem of third-party and partner applications to present actionable information for customer.

Share on Social Networks: